Cambridge, Massachusetts, United States
Dr. Nicolas Van de Velde is a global HEOR and Market Access leader with more than 25 years of experience translating science into payer-relevant value, reimbursement strategy, and patient access. At Moderna, he leads global HEOR across vaccines, oncology, and rare diseases. Previously, at ViiV Healthcare and GSK, he supported global launch and market access strategies for long-acting HIV therapies, pre-exposure prophylaxis, and major vaccine franchises. Dr. Van de Velde combines scientific depth with business leadership through an MBA from Imperial College London, a PhD in Epidemiology from Université Laval (Canada), an MSc in Infectious Diseases from St Mary’s Hospital (London), and a Master of Engineering in Biochemistry from École Polytechnique (Brussels). He has published over 100 articles, with 2,600+ citations, in leading journals in vaccinology, epidemiology, and public health. He is recognized for building evidence and access strategies across therapeutic areas that support HTA, pricing, reimbursement, and differentiated positioning in global markets.
All therapeutic areas
COVID-19 vaccines
Led the global HTA strategy for the launch of the first long-acting HIV treatment and pre-exposure prophylaxis
Launching Shingrix, the vaccine that protects elderly against shingles, submitted reimbursement dossiers for Bexsero which protects infants from deadly meningitis and its long-term sequelae, and supported all countries with tenders for pneumococcal vaccines.
Led HEOR and public health policy modeling through affiliations with Imperial College London and Université Laval, informing vaccination recommendations, reimbursement, and prevention strategy across multiple countries. Developed HPV-ADVISE, an agent-based model used by decision-makers in Canada, Europe, and the US to assess cost-effectiveness and optimize HPV vaccination scenarios. Presented evidence to major public health and advisory bodies including CDC, WHO, NACI, HCSP, INVS, and the Quebec Immunisation Committee. Published as first author in leading journals including American Journal of Epidemiology, Vaccine, and Journal of the National Cancer Institute, and was an invited speaker at IPV and EUROGIN. Advised Merck, MSD International, and Sanofi Aventis MSD on vaccination strategy, health economic modeling, and evidence generation for policy and regulatory review.
Led downstream purification activities for hepatitis B surface antigen in a regulated vaccine manufacturing environment. Accountable for product purity, process validation, and compliance in an FDA-audited setting. At an early stage in my career, represented the purification process during FDA inspections, including justification of manufacturing deviations. Built a strong foundation in GMP, quality, regulatory compliance, and operational leadership in vaccine manufacturing.